dronabinol has been researched along with Parkinson Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 7 (46.67) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, N; Hanna, A; Matos, A; Michaud, V; Pizzolato, K; Thacker, D; Toro-Pagán, ND; Turgeon, J | 1 |
| Algul, O; Ozcelik, I; Yucel, MA | 1 |
| Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S | 1 |
| Carbone, F; Djamshidian, A; Ellmerer, P; Goebel, G; Heim, B; Knaus, HG; Krejcy, K; Krismer, F; Marini, K; Peball, M; Poewe, W; Seppi, K; Stockner, H; Stolz, R; Ulmer, H; Valent, D; Wenning, GK; Werkmann, M | 1 |
| Cooray, R; Gupta, V; Suphioglu, C | 1 |
| Buhmann, C; Fründt, O; Hidding, U; Yenilmez, F | 1 |
| Haghparast, E; Komeili, G; Sheibani, V | 1 |
| Fox, SH; Freitas, ME; Lang, AE; Udow, SJ | 1 |
| Djamshidian, A; Ellmerer, P; Knaus, HG; Peball, M; Poewe, W; Seppi, K; Stolz, R; Ulmer, H; Valent, D; Werkmann, M | 1 |
| Carroll, CB; Eastwood, J; Hanemann, CO; McCorry, K; Zajicek, JP; Zeissler, ML | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
| Carroll, CB; Hanemann, CO; Zajicek, JP; Zeissler, ML | 1 |
| Hasegawa, T; Kameyama, T; Katsumata, Y; Kinoshita, H; Nabeshima, T; Yamamoto, I | 1 |
| Hart, LL; Nguyen, PB | 1 |
| Brotchie, JM; Crossman, AR; Dick, JP; Fox, SH; Hill, M; Sieradzan, KA | 1 |
2 review(s) available for dronabinol and Parkinson Disease
| Article | Year |
|---|---|
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Topics: Alzheimer Disease; Animals; Cannabidiol; Dronabinol; Endocannabinoids; Humans; Inflammation; Parkinson Disease | 2020 |
Dronabinol in tremor.
Topics: Age Factors; Dronabinol; Female; Humans; Male; Parkinson Disease; Primidone; Propranolol; Tremor | 1993 |
4 trial(s) available for dronabinol and Parkinson Disease
| Article | Year |
|---|---|
Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Topics: Cannabidiol; Cannabis; Cognition; Double-Blind Method; Dronabinol; Parkinson Disease | 2023 |
Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
Topics: Aged; Anxiety; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Parkinson Disease; Sleep Wake Disorders; Treatment Outcome | 2020 |
Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).
Topics: Antiparkinson Agents; Cannabinoid Receptor Agonists; Clinical Trial Protocols as Topic; Double-Blind Method; Dronabinol; Female; Humans; Male; Parkinson Disease; Patient Selection; Proof of Concept Study; Treatment Outcome | 2019 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug | 2001 |
9 other study(ies) available for dronabinol and Parkinson Disease
| Article | Year |
|---|---|
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease.
Topics: Cannabis; Dopamine Agents; Dronabinol; Hallucinations; Humans; Middle Aged; Parkinson Disease | 2021 |
Machine learning study: from the toxicity studies to tetrahydrocannabinol effects on Parkinson's disease.
Topics: Apomorphine; Dopamine Agonists; Dronabinol; Humans; Molecular Docking Simulation; Parkinson Disease | 2023 |
Cannabis in Parkinson's Disease: The Patients' View.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Female; Health Knowledge, Attitudes, Practice; Health Surveys; Humans; Male; Medical Marijuana; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Acceptance of Health Care; Patient Preference; Urban Population | 2021 |
Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Disease Models, Animal; Disks Large Homolog 4 Protein; Dronabinol; Dyskinesia, Drug-Induced; Male; Medical Marijuana; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Plant Extracts; Rats; Rats, Wistar; Receptors, Dopamine D1 | 2021 |
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.
Topics: Aged; Cannabinoids; Delusions; Dronabinol; Dystonia; Female; Hallucinations; Humans; Parkinson Disease; Psychoses, Substance-Induced | 2018 |
Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Dronabinol; Humans; Mitochondria; Mitochondrial Diseases; Neuroblastoma; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR gamma; Thiazolidinediones | 2016 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Herbicides; Humans; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Receptor, Cannabinoid, CB1; Tumor Cells, Cultured; Up-Regulation | 2012 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol; Haloperidol; Male; Mice; Oxotremorine; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1994 |